Novartis restructures its development strategy

Novartis CEO Daniel Vasella (photo) tells the Wall Street Journal that he knew Novartis had become too big and too bureaucratic when one of the company's top scientists expressed delight at finally meeting him. So he's set out to reconstruct the drug giant he built, with a particular emphasis on drug discovery.  

At the top of the pipeline: two meningitis vaccines that could become blockbusters. And the new pharma chief--Joe Jimenez--is breaking up investigators into small teams so they can go one on one with regulators to see if they should move ahead with a development program.

- read the article from the Wall Street Journal

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.